BioAtla, Inc. — fact timeline

BioAtla, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025, net income Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in.

“BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights – Initiated a formal process to monetize assets – Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.”

BioAtla, Inc. announced a restructuring with charges of between $0.5 and $0.6 million affecting the Company (approximately 70%).

“formal process to explore and evaluate strategic options to maximize shareholder value. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs. The Company expects to pay for the majority of these costs in the first quarter of 2026. The estimates of the”

BioAtla, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna”

BioAtla, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna”

BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).

“On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).”

BioAtla, Inc. issued one (1) share of preferred stock to Jay M. Short, Ph.D. for $0.01.

“to Jay M. Short, Ph.D., the Company’s Chairman, Chief Executive Officer and co-founder, for the purchase price of $0.01.”

BioAtla, Inc.: Filed Certificate of Designation for Series A Junior Preferred Stock (Super-Voting Share) establishing its voting, dividend, liquidation, redemption, and transfer terms (effective 2026-01-09).

“On January 9, 2026, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.”

BioAtla, Inc. entered into Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. valued at aggregate $40 million (effective 2025-12-30).

“On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”).”

BioAtla, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. valued at Standby Equity Purchase Agreement (effective 2025-11-20).

“Also on November 20, 2025 (the “Effective Date”), the Company entered into the Standby Equity Purchase Agreement (the “SEP”

BioAtla, Inc. entered into Pre-Paid Advance Agreement with YA II PN, Ltd.; Anson Investments Master Fund LP; Anson East Master Fund LP valued at $7.5 million Pre-Paid Advance; gross proceeds of approx. $7.13 million (effective 2025-11-20).

“On November 20, 2025, BioAtla, Inc. (the “Company”) entered into Pre-Paid Advance Agreements (the “PPAs”) with each of YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), Anson Investments Master Fund LP and Anson East Master Fund LP (collectively, the “Investors”).”

BioAtla, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“May 12, 2025, BioAtla, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that because the Company’s stockholders’ equity was $547,000 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, it was no longer in compliance with the $10,000,000 minimum stockholders’ equity requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(1)(A) (the “Minimum Stockholder Equity Requirement”), and th”

BioAtla, Inc. announced a restructuring with charges of $0.5 and $0.6 million (approximately 30%).

“On March 27, 2025, the Company announced a workforce reduction of approximately 30%. The foregoing actions were committed to on March 21, 2025 and are intended to streamline the Company’s operating cost structure to support development of its prioritized programs and set the Company up for long-term success. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs.”

BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because the Company has not maintained a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the last 30 consecutive business days. The Notice has no immediate effect on the listing or trading of the Company’s securities. The Company has 180 calendar days from the date of the Notice, or until Aug”

BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance wi”

BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.”

BioAtla, Inc.: Amended advance notice provisions for stockholder nominations and proposals, removing certain disclosure and interview requirements, clarifying cure periods and disclosure of financial supporters, and modifying definitions (effective 2024-04-22).

“On April 22, 2024, the board of directors (the “Board”) of BioAtla, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Bylaws”), which became immediately effective, and include, among other things, the following changes in Article I, Section 2 relating to advance notice requirements applicable to stockholder-submitted nominations and other business proposals (the “Advance Notice Bylaw”): • remove the requirement for a Proposing Person (as defined in the Advance Notice Bylaw) to disclose any knowledge that another person or entity is Acting in Concert (as defined in the Advance Notice Bylaw) in describing the material terms of any agreement, arrangement or understanding entered into for the purpose of acquiring, holding, disposing or voting shares of the Company’s stock; • clarify that a stockholder’s notice required by the Advance Notice Bylaw must disclose the names, addresses and Company stock ownership of record”

BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

“BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023”

Christian Vasquez changed role as Chief Accounting Officer, Controller and Corporate Secretary at BioAtla, Inc..

“On February 15, 2024, the Compensation Committee approved the promotion of Christian Vasquez from SVP of Finance to Chief Accounting Officer.”

BioAtla, Inc.: Amended and restated bylaws to conform to Delaware law, update advance notice provisions, and address universal proxy rules (effective 2024-01-05).

“On January 5, 2024, the board of directors (the “Board”) of BioAtla, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”), which became immediately effective.”

BioAtla, Inc. reported financial results for the third quarter ended September 30, 2023.

“On November 7, 2023, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023”

BioAtla, Inc. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa.

“Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.”

BioAtla, Inc. shareholders approved Non-binding advisory vote on executive compensation of named executive officers at the 2023-06-14 meeting.

“The Company’s stockholders approved, on a non-binding advisory basis, the executive compensation of our named executive officers by the following votes:”

BioAtla, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following votes:”

BioAtla, Inc. shareholders approved Election of three Class III directors at the 2023-06-14 meeting.

“The Company’s stockholders approved the election of three Class III directors to the Company’s Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal, by the following votes:”

BioAtla, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

“On March 23, 2023, BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.”

Scott Smith resigned as President at BioAtla, Inc..

“On February 24, 2023, Scott Smith, President of BioAtla, Inc. (“BioAtla”) notified BioAtla of his intention to resign, effective February 27, 2023, in order to pursue a new opportunity as Chief Executive Officer at Viatris Inc.”

Christian Vasquez changed role as SVP of Finance, Controller and Corporate Secretary at BioAtla, Inc..

“On February 9, 2023, the Compensation Committee approved the promotion of Christian Vasquez from VP of Finance to SVP of Finance.”

BioAtla, Inc. entered into Sales Agreement with Jefferies LLC valued at up to $100,000,000 (effective 2023-01-06).

“On January 6, 2023, BioAtla, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) under which the Company may offer and sell, from time to time in its sole discretion, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with aggregate gross sales proceeds of up to $100,000,000 through an “at the market” equity offering program under which Jefferies will act as sales agent.”

BioAtla, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at $65,000,004.00 (effective 2022-11-04).

“On November 4, 2022, BioAtla, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as underwriter (the “Underwriter”), pursuant to which, the Company agreed to issue and sell to the Underwriter, and the Underwriter has agreed to purchase from the Company, an aggregate of 9,745,128 shares (the “Shares”) of its common stock, par value $0.0001 per share.”

BioAtla, Inc. reported financial results for third quarter ended September 30, 2022.

“BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022”

Guy Levy resigned as Director at BioAtla, Inc..

“On June 3, 2022, Guy Levy informed BioAtla, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective June 16, 2022, the date of the Company’s 2022 Annual Meeting of Shareholders.”

Edward L. Williams was appointed as Director at BioAtla, Inc..

“On December 16, 2021, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Edward L. (Eddie) Williams to the Board, effective December 16, 2021.”